Poplar Forest Capital LLC Maintains Holdings in Bristol-Myers Squibb Company (BMY)

Poplar Forest Capital LLC continued to hold its position in shares of Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 24,550 shares of the biopharmaceutical company’s stock at the end of the second quarter. Poplar Forest Capital LLC’s holdings in Bristol-Myers Squibb were worth $1,368,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Connecticut Wealth Management LLC bought a new stake in Bristol-Myers Squibb in the first quarter valued at approximately $224,000. Birmingham Capital Management Co. Inc. AL boosted its holdings in Bristol-Myers Squibb by 4.4% in the first quarter. Birmingham Capital Management Co. Inc. AL now owns 70,973 shares of the biopharmaceutical company’s stock valued at $3,860,000 after acquiring an additional 3,000 shares during the last quarter. HGK Asset Management Inc. boosted its holdings in Bristol-Myers Squibb by 20.8% in the first quarter. HGK Asset Management Inc. now owns 308,825 shares of the biopharmaceutical company’s stock valued at $16,794,000 after acquiring an additional 53,221 shares during the last quarter. Investment Partners Ltd. OH ADV boosted its holdings in Bristol-Myers Squibb by 1.4% in the first quarter. Investment Partners Ltd. OH ADV now owns 20,350 shares of the biopharmaceutical company’s stock valued at $1,107,000 after acquiring an additional 274 shares during the last quarter. Finally, Goelzer Investment Management Inc. boosted its holdings in Bristol-Myers Squibb by 85.4% in the first quarter. Goelzer Investment Management Inc. now owns 75,402 shares of the biopharmaceutical company’s stock valued at $4,100,000 after acquiring an additional 34,735 shares during the last quarter. 69.82% of the stock is owned by institutional investors.

Bristol-Myers Squibb Company (NYSE BMY) opened at $60.97 on Thursday. The stock has a market capitalization of $101,508.14, a P/E ratio of 20.95, a price-to-earnings-growth ratio of 2.35 and a beta of 1.18. Bristol-Myers Squibb Company has a twelve month low of $46.01 and a twelve month high of $66.10. The company has a current ratio of 1.59, a quick ratio of 1.46 and a debt-to-equity ratio of 0.47.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. During the same period in the previous year, the company earned $0.77 earnings per share. Bristol-Myers Squibb’s revenue for the quarter was up 6.7% compared to the same quarter last year. sell-side analysts anticipate that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current fiscal year.

In other news, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.23% of the stock is owned by corporate insiders.

Several analysts recently commented on BMY shares. Goldman Sachs Group reiterated a “buy” rating and issued a $65.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Thursday, September 7th. Vetr cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $63.81 target price on the stock. in a report on Wednesday, August 9th. Jefferies Group reiterated a “buy” rating and issued a $66.00 target price (up from $63.00) on shares of Bristol-Myers Squibb in a report on Thursday, August 24th. UBS reiterated a “buy” rating and issued a $72.00 target price (up from $62.00) on shares of Bristol-Myers Squibb in a report on Friday, October 6th. Finally, Citigroup increased their price target on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. Bristol-Myers Squibb currently has a consensus rating of “Hold” and a consensus price target of $64.93.

TRADEMARK VIOLATION WARNING: “Poplar Forest Capital LLC Maintains Holdings in Bristol-Myers Squibb Company (BMY)” was originally posted by Transcript Daily and is the sole property of of Transcript Daily. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this piece of content can be viewed at https://transcriptdaily.com/2017/12/07/poplar-forest-capital-llc-maintains-holdings-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply